TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study

Naveen Seecheran, Victoria Seebalack, Rajeev Seecheran, Aarti Maharaj, Brent Boodhai, Valmiki Seecheran, Sangeeta Persad, Shastri Motilal, Antonio Tello-Montoliu, David Schneider, Naveen Seecheran, Victoria Seebalack, Rajeev Seecheran, Aarti Maharaj, Brent Boodhai, Valmiki Seecheran, Sangeeta Persad, Shastri Motilal, Antonio Tello-Montoliu, David Schneider

Abstract

Introduction: This prospective study aimed to determine whether trimetazidine (TMZ) alters the pharmacodynamic (PD) effects of clopidogrel.

Methods: Patients with stable coronary artery disease (SCAD) (n = 24) who were actively treated with dual antiplatelet therapy (DAPT) of aspirin 81 mg daily and clopidogrel 75 mg daily were recruited. Platelet function was measured with the VerifyNow P2Y12 assay (Accriva Diagnostics, San Diego, CA, USA) and assessed before the initiation of and after 14 days of treatment with TMZ. Results were compared using a paired t test.

Results: Almost 80% of the study population were of South Asian descent and had diabetes mellitus (DM). P2Y12 reaction units (PRUs) were higher in patients on TMZ (204 ± 56 compared with 174 ± 71 before TMZ, p = 0.005). The average increase in PRU score was 29 (95% confidence interval 8.8-49.7). Before TMZ, the proportion of patients with high on-treatment platelet reactivity (PRU > 208 units) was 25%, which increased to 42% for patients on TMZ.

Conclusion: Higher platelet reactivity was seen in patients on TMZ, suggesting that TMZ attenuated the PD effects of clopidogrel in this study of a predominantly South Asian diabetic subpopulation. Alternative therapies should be considered and further research is warranted.

Trial registration: ClinicalTrials.gov number, NCT03603249.

Keywords: Clopidogrel; Platelet reactivity; Trimetazidine.

Figures

Fig. 1
Fig. 1
Methodology outline
Fig. 2
Fig. 2
Individual patient baseline P2Y12 reaction units (PRU) compared to PRU score on TMZ

References

    1. Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–2273. doi: 10.1016/j.jacc.2013.07.101.
    1. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362. doi: 10.1056/NEJMoa0809171.
    1. Matetzky S, Shenkman B, Guetta V. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ACC Curr J Rev. 2004;13(9):9. doi: 10.1016/j.accreview.2004.08.004.
    1. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32(4):525–527. doi: 10.2337/dc08-1865.
    1. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12:30–47. doi: 10.1038/nrcardio.2014.156.
    1. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157–1164. doi: 10.1016/j.jacc.2005.01.034.
    1. Angiolillo Dominick J., Ueno Masafumi, Goto Shinya. Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal. 2010;74(4):597–607. doi: 10.1253/circj.CJ-09-0982.
    1. Kantor Paul F., Lucien Arnaud, Kozak Raymond, Lopaschuk Gary D. The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase. Circulation Research. 2000;86(5):580–588. doi: 10.1161/01.RES.86.5.580.
    1. Chrusciel Piotr, Rysz Jacek, Banach Maciej. Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease. Drugs. 2014;74(9):971–980. doi: 10.1007/s40265-014-0233-5.
    1. Cross Heather R. Trimetazidine for stable angina pectoris. Expert Opinion on Pharmacotherapy. 2001;2(5):857–875. doi: 10.1517/14656566.2.5.857.
    1. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundamental Clin Pharmacol. 2003;17:133–145. doi: 10.1046/j.1472-8206.2003.00154.x.
    1. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:854. doi: 10.1016/s0002-8703(03)00415-0.
    1. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. British Journal of Clinical Pharmacology. 1994;37(3):279–288. doi: 10.1111/j.1365-2125.1994.tb04276.x.
    1. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780–2792. doi: 10.1093/eurheartj/ehy301.
    1. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48(5):992–998. doi: 10.1016/j.jacc.2006.03.060.
    1. Ambesh P, Kazmi DH, Kapoor A, Sinha A, Khanna R, Kumar S, et al. Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention associated myocardial injury. J Am College Cardiol. 2018;71:A1438. doi: 10.1016/s0735-1097(18)31979-x.
    1. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2949–3003. 10.1093/eurheartj/eht296.
    1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847. 10.1093/eurheartj/ehs104.
    1. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2012;65:173. 10.1016/j.rec.2011.11.006.
    1. McClellan KJ, Plosker GL. Trimetazidine. Drugs. 1999;58:143–157. doi: 10.2165/00003495-199958010-00016.
    1. Marzilli M. Trimetazidine: a metabolic agent for the treatment of stable angina. Eur Heart J Suppl. 2001;3:O12. doi: 10.1016/s1520-765x(01)90149-x.
    1. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005. 10.1002/14651858.cd003614.pub2.
    1. Szwed H. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II) European Heart Journal. 2001;22(24):2267–2274. doi: 10.1053/euhj.2001.2896.
    1. Chazov E. I., Lepakchin V. K., Zharova E. A., Fitilev S. B., Levin A. M., Rumiantzeva E. G., Fitileva T. B. Trimetazidine in Angina Combination Therapy-The TACT Study: Trimetazidine versus Conventional Treatment in Patients with Stable Angina Pectoris in a Randomized, Placebo-Controlled, Multicenter Study. American Journal of Therapeutics. 2005;12(1):35–42. doi: 10.1097/00045391-200501000-00006.
    1. Coats Caroline J., Pavlou Menelaos, Watkinson Oliver T., Protonotarios Alexandros, Moss Linda, Hyland Rebecca, Rantell Khadija, Pantazis Antonis A., Tome Maite, McKenna William J., Frenneaux Michael P., Omar Rumana, Elliott Perry M. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy. JAMA Cardiology. 2019;4(3):230. doi: 10.1001/jamacardio.2018.4847.
    1. Christie B. Doctors revise Declaration of Helsinki. BMJ. 2000;321(7266):913–913. doi: 10.1136/bmj.321.7266.913.
    1. D′Agostino RB, Sullivan L, Massaro J, editors. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). In: Wiley Encyclopedia of Clinical Trials. Hoboken, NJ: Wiley; 2008. 10.1002/9780471462422.eoct457.
    1. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, et al. A pharmacodynamic comparison of prasugrel vs high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011;32(7):838–846. doi: 10.1093/eurheartj/ehq494.
    1. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017–1023. doi: 10.1016/j.jacc.2010.02.072.
    1. Seecheran NA, Maharaj A, Boodhai B, Seecheran R, Seecheran V, Persad S, et al. Prevalence of clOpidogrel “resIstaNce” in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. Open Heart. 2019;6(1):e000841. doi: 10.1136/openhrt-2018-000841.
    1. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundamental Clin Pharmacol. 2003;17:133–145. doi: 10.1046/j.1472-8206.2003.00154.x.
    1. Hourani SMO. Discovery and recognition of purine receptor subtypes on platelets. Drug Dev Res. 2001;52:140–149. doi: 10.1002/ddr.1108.
    1. Stafford Nicholas P., Pink Andrew E., White Ann E., Glenn Jacqueline R., Heptinstall Stan. Mechanisms Involved in Adenosine Triphosphate–Induced Platelet Aggregation in Whole Blood. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(10):1928–1933. doi: 10.1161/01.ATV.0000089330.88461.D6.
    1. Coade S B, Pearson J D. Metabolism of adenine nucleotides in human blood. Circulation Research. 1989;65(3):531–537. doi: 10.1161/01.RES.65.3.531.
    1. Birk AV, Johan Broekman M, Gladek EM, Robertson HD, Drosopoulos JHF, Marcus AJ, et al. Role of extracellular ATP metabolism in regulation of platelet reactivity. J Lab Clin Med. 2002;140:166–175. doi: 10.1067/mlc.2002.126719.
    1. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood. 1989;74(4):1181–1195. doi: 10.1182/blood.V74.4.1181.1181.
    1. Nicholas RA. Identification of the P2Y(12) receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides. Mol Pharmacol. 2001;60(3):416–20. .
    1. Willoughby SR, Chirkov YY, Kennedy JA, Murphy GA, Chirkova LP, Horowitz JD. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol. 1998;356:207–213. doi: 10.1016/s0014-2999(98)00527-5.
    1. Astarie-Dequeker Catherine, Joulin Yves, Devynck Marie-Aude. Inhibitory Effect of Trimetazidine on Thrombin-Induced Aggregation and Calcium Entry into Human Platelets. Journal of Cardiovascular Pharmacology. 1994;23(3):401–407. doi: 10.1097/00005344-199423030-00007.
    1. Devynck Marie-Aude, Hanh Le Quan Sang Kin, Joulin Yves, Mazeaud Madeleine. Acute membrane effects of trimetazidine in human platelets. European Journal of Pharmacology: Molecular Pharmacology. 1993;245(2):105–110. doi: 10.1016/0922-4106(93)90117-R.
    1. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19. doi: 10.1056/NEJMoa1112277.
    1. Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–1808. doi: 10.1016/S0140-6736(17)30751-1.
    1. Gibson C. Michael, Mehran Roxana, Bode Christoph, Halperin Jonathan, Verheugt Freek W., Wildgoose Peter, Birmingham Mary, Ianus Juliana, Burton Paul, van Eickels Martin, Korjian Serge, Daaboul Yazan, Lip Gregory Y.H., Cohen Marc, Husted Steen, Peterson Eric D., Fox Keith A. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine. 2016;375(25):2423–2434. doi: 10.1056/NEJMoa1611594.
    1. Seecheran N, Nandlal N, Nankissoon S, Nancoo C, Nelson C, Nkemakolam A, et al. A Trinidadian cardiovascular medication adherence survey: the ADHERE TNT study. Int J Commun Med Publ Health. 2017;4:3601. doi: 10.18203/2394-6040.ijcmph20174218.
    1. Toso A, De Servi S, Leoncini M, Angiolillo DJ, Calabrò P, Piscione F, et al. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. J Thromb Thrombolysis. 2017;44(3):355–361. doi: 10.1007/s11239-017-1541-x.
    1. Godino Cosmo, Pavon Anna Giulia, Mangieri Antonio, Salerno Anna, Cera Michela, Monello Alberto, Chieffo Alaide, Magni Valeria, Cappelletti Alberto, Margonato Alberto, Colombo Antonio. Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study. Clinical Cardiology. 2017;40(8):605–611. doi: 10.1002/clc.22709.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner